Akèy › Leksemi biphenotipik egi › Distrik Columbia › Washington

Etid klinik pou Leksemi biphenotipik egi nan Washington, DC

4 etid pou Leksemi biphenotipik egi ap chèche patisipan nan sit nan ak bò kote Washington (nan yon distans apeprè 30 mil). Louvri yon etid pou wè ki moun ki ka patisipe ak kijan pou kontakte ekip etid la.

Tèks ofisyèl etid la (Anglè)

Ap chèche patisipan pou yon etid? Mete l anwo paj sa a — $99 pou 30 jou →

Testing the Addition of the Anti-cancer Drug Venetoclax and/or the Anti-cancer Immunotherapy Blinatumomab to the Usual Chemotherapy Treatment for Infants With Newly Diagnosed KMT2A-rearranged or KMT2A-non-rearranged Leukemia

Ap rekriteFaz 2

Children's National Medical Center, Washington D.C.

365 Days · Tout sèks · Mizajou Sep 25, 2026 · NCT06317662

Inotuzumab Ozogamicin and Post-Induction Chemotherapy in Treating Patients With High-Risk B-ALL, Mixed Phenotype Acute Leukemia, and B-LLy

Ap rekriteFaz 3

Children's National Medical Center, Washington D.C.
Walter Reed National Military Medical Center, Bethesda · 7 mi lwen

365 Days – 25 Years · Tout sèks · Mizajou Aug 25, 2026 · NCT03959085

The Pediatric Acute Leukemia (PedAL) Screening Trial - A Study to Test Bone Marrow and Blood in Children With Leukemia That Has Come Back After Treatment or Is Difficult to Treat - A Leukemia & Lymphoma Society and Children's Oncology Group Study

Ap rekriteFaz 1/2

Children's National Medical Center, Washington D.C.

Jiska laj 22 · Tout sèks · Mizajou Aug 25, 2026 · NCT04726241

Tagraxofusp in Pediatric Patients With Relapsed or Refractory CD123 Expressing Hematologic Malignancies

Ap rekriteFaz 1

Children's National Medical Center, Washington D.C.
National Cancer Institute, Pediatric Oncology Branch, Bethesda · 7 mi lwen

Laj 1 a 21 · Tout sèks · Mizajou Dec 6, 2024 · NCT05476770

Etid Leksemi biphenotipik egi nan lòt vil

Lòt etid nan Washington

Sous ClinicalTrials.gov, done yo ranmase Oct 6, 2026. Chak etid gen kritè li pou li menm; ekip etid la deside ki moun ki ka patisipe.